4//SEC Filing
Chevallard Daniel R. 4
Accession 0001209191-23-047665
CIK 0001061027other
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 6:47 PM ET
Size
9.8 KB
Accession
0001209191-23-047665
Insider Transaction Report
Form 4
Chevallard Daniel R.
Chief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-08-25−6,888→ 48,222 total→ Common Stock (6,888 underlying) - Exercise/Conversion
Common Stock
2023-08-25+6,888→ 99,165 total - Sale
Common Stock
2023-08-28$1.45/sh−3,512$5,092→ 95,653 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
- [F2]The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
- [F3]One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.
Documents
Issuer
Viracta Therapeutics, Inc.
CIK 0001061027
Entity typeother
Related Parties
1- filerCIK 0001706176
Filing Metadata
- Form type
- 4
- Filed
- Aug 28, 8:00 PM ET
- Accepted
- Aug 29, 6:47 PM ET
- Size
- 9.8 KB